{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:21:40Z","timestamp":1794961300968,"version":"4.9.1"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.neuropharm.2023.109528","type":"journal-article","created":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T01:15:19Z","timestamp":1680398119000},"page":"109528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs"],"prefix":"10.1016","volume":"233","author":[{"given":"Farah Z.","family":"Zia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Belouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Dworkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid H.","family":"Ghauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Henningfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K.","family":"Lanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.neuropharm.2023.109528_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207820","article-title":"The National Institutes of Health measure of healing experience of all life stressors (NIH-HEALS): factor analysis and validation","volume":"13","author":"Ameli","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2023.109528_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109528_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jama.2021.13300","article-title":"The helping to end addiction long-term (HEAL) initiative of the National Institutes of Health","volume":"326","author":"Baker","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109528_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106133","article-title":"Functional reorganization of the default mode network across chronic pain conditions","volume":"9","author":"Baliki","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109528_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109214","article-title":"Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines","volume":"219","author":"Belouin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109528_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109528_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatr."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109528_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/nbdi.1999.0262","article-title":"The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia","volume":"6","author":"Bondy","year":"1999","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109528_bib10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1471-4159.2005.03485.x","article-title":"The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity","volume":"95","author":"Bortolozzi","year":"2005","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109528_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1099-1611(199909\/10)8:5<417::AID-PON398>3.0.CO;2-4","article-title":"A case for including spirituality in quality of life measurement in oncology","volume":"8","author":"Brady","year":"1999","journal-title":"Psycho Oncol."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/jpm.2017.0684","article-title":"Taking psychedelics seriously","volume":"21","author":"Byock","year":"2018","journal-title":"J. Palliat. Med."},{"issue":"8","key":"10.1016\/j.neuropharm.2023.109528_bib13","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00213-020-05533-9","article-title":"Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan","volume":"237","author":"Carbonaro","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109528_bib14","series-title":"THIS ISSUE","author":"Carhart-Harris","year":"2022"},{"issue":"15","key":"10.1016\/j.neuropharm.2023.109528_bib15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109528_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics","volume":"71","author":"Carhart-Harris","year":"2019","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.neuropharm.2023.109528_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/rapm-2020-101273","article-title":"Chronic pain and psychedelics: a review and proposed mechanism of action","volume":"45","author":"Castellanos","year":"2020","journal-title":"Reg. Anesth. Pain Med."},{"issue":"10289","key":"10.1016\/j.neuropharm.2023.109528_bib18","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1124\/jpet.119.259408","article-title":"The opioid crisis and the future of addiction and pain therapeutics","volume":"371","author":"Coussens","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/wps.21069","article-title":"Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients","volume":"22","author":"Cuijpers","year":"2023","journal-title":"World Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/wps.20701","article-title":"A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression","volume":"19","author":"Cuijpers","year":"2020","journal-title":"World Psychiatr."},{"issue":"36","key":"10.1016\/j.neuropharm.2023.109528_bib22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109528_bib23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109528_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics","volume":"12","author":"de Vos","year":"2021","journal-title":"Front. Psychiatr."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2023.109528_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1124\/pharmrev.121.000514","article-title":"Self-Entropic Broadening Theory: toward a new understanding of self and behavior change informed by psychedelics and psychosis","volume":"74","author":"Dourron","year":"2022","journal-title":"Pharmacol. Rev."},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109528_bib27","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jpain.2022.05.003","article-title":"If the doors of perception were cleansed, would chronic pain be relieved? Evaluating the benefits and risks of psychedelics","volume":"23","author":"Dworkin","year":"2022","journal-title":"J. Pain"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib28","doi-asserted-by":"crossref","first-page":"e886","DOI":"10.1097\/PR9.0000000000000886","article-title":"The ACTTION Guide to Clinical Trials of Pain Treatments, part II: mitigating bias, maximizing value","volume":"6","author":"Dworkin","year":"2021","journal-title":"Pain Rep"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2023.109528_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109528_bib30","series-title":"THIS ISSUE","author":"Erritzoe","year":"2022"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109528_bib31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1526-4610.1977.hed1703118.x","article-title":"Brief report: phantom limp pain: sub-hallucinogenic treatment with lysergic acid diethylamide (LSD-25)","volume":"17","author":"Fanciullacci","year":"1977","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int. Rev. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881121991822","article-title":"Optimal dosing for psilocybin pharmacotherapy: considering weight-adjusted and fixed dosing approaches","volume":"35","author":"Garcia-Romeu","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bjae.2017.09.001","article-title":"Living well with chronic pain: the role of pain-management programmes","volume":"18","author":"Gauntlett-Gilbert","year":"2018","journal-title":"BJA Educ"},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109528_bib35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/acsptsci.2c00177","article-title":"Structure-activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice","volume":"5","author":"Glatfelter","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"18","key":"10.1016\/j.neuropharm.2023.109528_bib36","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109528_bib37","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jpain.2013.06.008","article-title":"An overview of animal models of pain: disease models and outcome measures","volume":"14","author":"Gregory","year":"2013","journal-title":"J. Pain"},{"issue":"12","key":"10.1016\/j.neuropharm.2023.109528_bib38","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109528_bib39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology (Berl)."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatr."},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109528_bib41","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1592\/phco.21.13.1070.34622","article-title":"Adjunctive agents in the management of chronic pain","volume":"21","author":"Guay","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2023.109528_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2019.105852","article-title":"The nexus of opioids, pain, and addiction: challenges and solutions","volume":"128","author":"Henningfield","year":"2019","journal-title":"Prev. Med."},{"key":"10.1016\/j.neuropharm.2023.109528_bib43","doi-asserted-by":"crossref","first-page":"109220","DOI":"10.1016\/j.neuropharm.2022.109220","article-title":"Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling","volume":"218","author":"Henningfield","year":"2022","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/0021-8294.00085","article-title":"Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran","volume":"40","author":"Hood","year":"2001","journal-title":"J. Sci. Stud. Relig."},{"key":"10.1016\/j.neuropharm.2023.109528_bib45","article-title":"Relieving pain in America: a blueprint for transforming prevention, care, education, and research","year":"2011","journal-title":"Committee on Advancing Pain Research, Care, and Education"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib46","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/acsptsci.0c00198","article-title":"Consciousness, religion, and gurus: pitfalls of psychedelic medicine","volume":"4","author":"Johnson","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/02791072.2020.1762023","article-title":"Can psychedelics alleviate symptoms of cluster headache and accompanying mental health problems? A case report involving Hawaiian baby woodrose","volume":"52","author":"Johnson","year":"2020","journal-title":"J. Psychoact. Drugs"},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109528_bib48","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1177\/0333102410363490","article-title":"The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series","volume":"30","author":"Karst","year":"2010","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib49","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/BF01575629","article-title":"Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide","volume":"41","author":"Kast","year":"1967","journal-title":"Psychiatr. Q."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib50","doi-asserted-by":"crossref","first-page":"e845","DOI":"10.1097\/PR9.0000000000000854","article-title":"Design and conduct of confirmatory chronic pain clinical trials","volume":"6","author":"Katz","year":"2021","journal-title":"Pain Rep"},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/082585970402000402","article-title":"The Demoralization Scale: a report of its development and preliminary validation","volume":"20","author":"Kissane","year":"2004","journal-title":"J. Palliat. Care"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib52","first-page":"22","article-title":"The effect of LSD on the phantom limb phenomenon","volume":"87","author":"Kuromaru","year":"1967","journal-title":"J. Lancet"},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109528_bib53","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109528_bib54","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/hbm.23234","article-title":"LSD-induced entropic brain activity predicts subsequent personality change","volume":"37","author":"Lebedev","year":"2016","journal-title":"Hum. Brain Mapp."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0014-2999(89)90409-3","article-title":"Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment","volume":"163","author":"Leysen","year":"1989","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109528_bib56","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0893-133X(89)90010-9","article-title":"Chronic treatment with (+\/-)DOI, a psychotomimetic 5-HT2 agonist, downregulates 5-HT2 receptors in rat brain","volume":"2","author":"McKenna","year":"1989","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109528_bib58","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1523\/JNEUROSCI.09-10-03482.1989","article-title":"Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin","volume":"9","author":"McKenna","year":"1989","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109528_bib59","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrn2606","article-title":"Animal models of pain: progress and challenges","volume":"10","author":"Mogil","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109528_bib61","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.nicl.2018.03.005","article-title":"Altered network hub connectivity after acute LSD administration","volume":"18","author":"M\u00fcller","year":"2018","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.neuropharm.2023.109528_bib62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/bs.pbr.2018.08.004","article-title":"Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: contributions of the resting brain","volume":"242","author":"M\u00fcller","year":"2018","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109528_bib63","series-title":"NICE Guideline, No. 193","year":"2021"},{"issue":"50","key":"10.1016\/j.neuropharm.2023.109528_bib64","doi-asserted-by":"crossref","first-page":"20709","DOI":"10.1073\/pnas.1214605109","article-title":"Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry","volume":"109","author":"Navratilova","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109528_bib65","first-page":"810","volume":"63","author":"Nicholl","year":"2011","journal-title":"HTR2A polymorphisms with chronic widespread pain extent of musculoskeletal pain: results from two population-based cohorts. Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109528_bib66","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1021\/acschemneuro.8b00043","article-title":"Dark classics in chemical neuroscience: lysergic acid diethylamide (LSD)","volume":"9","author":"Nichols","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109528_bib67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3940(02)01256-9","article-title":"Serotonin receptor mRNA expression in rat dorsal root ganglion neurons","volume":"337","author":"Nicholson","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2023.109528_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109257","article-title":"Psychedelics therapeutics: \u2013 what we know, what we think, and what we need to research","volume":"223","author":"Nutt","year":"2023","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2023.109528_bib69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(02)00070-2","article-title":"5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats","volume":"99","author":"Okamoto","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109528_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109127","article-title":"Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations","volume":"214","author":"Ortiz","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109528_bib71","series-title":"Draft Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations","year":"2018"},{"key":"10.1016\/j.neuropharm.2023.109528_bib72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuropharm.2018.09.028","article-title":"Modality selective roles of pro-nociceptive spinal 5-HT(2A) and 5-HT(3) receptors in normal and neuropathic states","volume":"143","author":"Patel","year":"2018","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.npp.1300819","article-title":"Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex","volume":"31","author":"Pehek","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"15","key":"10.1016\/j.neuropharm.2023.109528_bib74","article-title":"Gabapentin can decrease acute pain and morphine consumption in spinal surgery patients: a meta-analysis of randomized controlled trials","volume":"96","author":"Peng","year":"2017","journal-title":"Medicine (Baltim.)"},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109528_bib75","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","article-title":"The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises","volume":"161","author":"Raja","year":"2020","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib76","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1037\/a0021767","article-title":"Assessing hopelessness in terminally ill cancer patients: development of the Hopelessness Assessment in Illness Questionnaire","volume":"23","author":"Rosenfeld","year":"2011","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.neuropharm.2023.109528_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109174","article-title":"Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care","volume":"216","author":"Ross","year":"2022","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2023.109528_bib79","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109528_bib80","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tins.2020.11.008","article-title":"A dendrite-focused framework for understanding the actions of ketamine and psychedelics","volume":"44","author":"Savalia","year":"2021","journal-title":"Trends Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109528_bib81","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","article-title":"Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey","volume":"47","author":"Schindler","year":"2015","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2023.109528_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109166","article-title":"Psychedelics as preventive treatment in headache and chronic pain disorders","volume":"215","author":"Schindler","year":"2022","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib83","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2023.109528_bib84","series-title":"THIS ISSUE","author":"Sellers","year":"2022"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109528_bib85","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopsych.2019.10.018","article-title":"The mesolimbic dopamine system in chronic pain and associated affective comorbidities","volume":"87","author":"Serafini","year":"2020","journal-title":"Biol. Psychiatr."},{"issue":"12","key":"10.1016\/j.neuropharm.2023.109528_bib86","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109528_bib87","first-page":"227","article-title":"Prevalence and characteristics of chronic phantom limb pain among American veterans. Results of a trial survey","volume":"62","author":"Sherman","year":"1983","journal-title":"Am. J. Phys. Med."},{"key":"10.1016\/j.neuropharm.2023.109528_bib88","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jad.2022.11.046","article-title":"Psilocybin-assisted therapy mediates psycho-social-spiritual change in cancer patients","volume":"323","author":"Shnayder","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109528_bib89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/PROM.S118696","article-title":"An assessment of meaning in life-threatening illness: development of the Healing Experience in All Life Stressors (HEALS)","volume":"8","author":"Sloan","year":"2017","journal-title":"Patient Relat. Outcome Meas."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib90","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109528_bib91","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/02791072.2016.1234090","article-title":"The associations of naturalistic classic psychedelic use, mystical experience, and creative problem solving","volume":"48","author":"Sweat","year":"2016","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2023.109528_bib92","article-title":"Editorial: preclinical animal models and measures of pain: improving predictive validity for analgesic drug development","volume":"3","author":"Tappe-Theodor","year":"2022","journal-title":"Front Pain Res (Lausanne)"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib93","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/00221309.1970.9920634","article-title":"The construction and validation of a death anxiety scale","volume":"82","author":"Templer","year":"1970","journal-title":"J. Gen. Psychol."},{"issue":"10289","key":"10.1016\/j.neuropharm.2023.109528_bib94","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(21)01194-6","article-title":"Rethinking chronic pain","volume":"397","author":"The Lancet","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib96","doi-asserted-by":"crossref","first-page":"e643","DOI":"10.1097\/PR9.0000000000000643","article-title":"The International Association for the Study of Pain definition of pain: as valid in 2018 as in 1979, but in need of regularly updated footnotes","volume":"3","author":"Treede","year":"2018","journal-title":"Pain Rep"},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109528_bib97","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/j.pain.0000000000000160","article-title":"A classification of chronic pain for ICD-11","volume":"156","author":"Treede","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109528_bib98","series-title":"Guidance for Industry. Analgesic Indications: Developing Drug and Biological Products","year":"2014"},{"key":"10.1016\/j.neuropharm.2023.109528_bib99","article-title":"Development of non-opioid analgesics for acute pain","year":"2022","journal-title":"Draft Guidance for Industry. U.S. Department of Health and Human Services"},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109528_bib100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11916-019-0803-z","article-title":"Off-label antidepressant use for treatment and management of chronic pain: evolving understanding and comprehensive review","volume":"23","author":"Urits","year":"2019","journal-title":"Curr. Pain Headache Rep."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109528_bib101","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1155\/2015\/196025","article-title":"Pain management strategies and lessons from the military: a narrative review","volume":"20","author":"Vallerand","year":"2015","journal-title":"Pain Res. Manag."},{"issue":"8","key":"10.1016\/j.neuropharm.2023.109528_bib102","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euroneuro.2010.03.008","article-title":"Exploring the brain network: a review on resting-state fMRI functional connectivity","volume":"20","author":"van den Heuvel","year":"2010","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109528_bib103","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2307\/1386666","article-title":"Testing the death transcendence scale","volume":"32","author":"Vandecreek","year":"1993","journal-title":"J. Sci. Stud. Relig."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109528_bib104","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1523\/JNEUROSCI.3822-08.2009","article-title":"Mood influences supraspinal pain processing separately from attention","volume":"29","author":"Villemure","year":"2009","journal-title":"J. Neurosci."},{"issue":"13","key":"10.1016\/j.neuropharm.2023.109528_bib105","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain--misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109528_bib106","series-title":"UCSF Launches New Psychedelic Research Division. Psychedelic Spotlight","author":"Walker-Journey","year":"2021"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109528_bib107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/pmt-2017-0068","article-title":"Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?","volume":"8","author":"Whelan","year":"2018","journal-title":"Pain Manag."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib108","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0306-4522(98)00653-8","article-title":"Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo","volume":"91","author":"Willins","year":"1999","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109528_bib109","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pain.2005.12.014","article-title":"Mesolimbic dopaminergic mechanisms and pain control","volume":"120","author":"Wood","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109528_bib110","series-title":"Quality of Life Assessment: International Perspectives","article-title":"The development of the World Health Organization quality of life assessment instrument (the WHOQOL)","year":"1994"},{"key":"10.1016\/j.neuropharm.2023.109528_bib111","series-title":"International Classification of Diseases, Eleventh Revision (ICD-11)","year":"2019"},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109528_bib112","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s12325-020-01354-6","article-title":"Limited utility for benzodiazepines in chronic pain management: a narrative review","volume":"37","author":"Wright","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.neuropharm.2023.109528_bib113","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2022.2546","article-title":"Preparing for the bursting of the psychedelic hype bubble","author":"Yaden","year":"2022","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109528_bib114","author":"Yale University"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109528_bib115","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/jpet.108.143461","article-title":"Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency","volume":"327","author":"Yu","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823001181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823001181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:24:27Z","timestamp":1758439467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823001181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":114,"alternative-id":["S0028390823001181"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109528","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109528"}}